FAQs

A doctor will need to interpret the test results to consider appropriate treatment options. Learn more about deletions.

AMONDYS 45 is used to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 45. Learn how gene mutations are identified.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Individuals who are allergic to casimersen or any of the ingredients in AMONDYS 45 should not receive AMONDYS 45. Serious allergic reactions to casimersen have included anaphylaxis, which may include difficulty breathing, tightness in the chest, and angioedema, which may include swelling of the mouth, face, lips, or tongue.

Yes. AMONDYS 45 is being studied in an ongoing clinical trial. See clinical trial results.

Weekly infusions of AMONDYS 45 helped the body make a shorter form of the dystrophin protein.^a View the results from an ongoing clinical study.
 

AMONDYS 45 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 45.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

^aBoys treated with AMONDYS 45 showed varying levels of increased dystrophin production after 48 weeks. In an ongoing clinical study, 27 boys (median age 9 years) receiving AMONDYS 45 had an average dystrophin level of 1.74% of normal, compared to 0.76% in 16 boys who received a placebo infusion.

Exon skipping allows the body to make a shorter form of the dystrophin protein.  Learn more about exon skipping.

A genetic test will confirm a diagnosis of Duchenne and allow your child’s doctor to identify the genetic mutation, so treatment options can be considered, and to assist with family planning. Understanding genetic testing.

Amenability describes the potential for your child to be treated with exon-skipping therapy. AMONDYS 45 is only for those whose Duchenne muscular dystrophy is the result of a genetic mutation amenable to exon 45 skipping. Find out more about genetic testing for Duchenne.

If your child has been diagnosed with Duchenne, you can request a genetic test through your child’s doctor. Once you have the results, your doctor or a genetic counselor can interpret them for you. Find out more about genetic testing for Duchenne.

A doctor will need to interpret the test results to consider appropriate treatment options. Learn more about deletions.

Getting a genetic test usually involves providing a blood or saliva sample. Find out more about genetic testing for Duchenne.

A mutation is a change in a person's DNA. Mutations range in size from a small (a single rung on a ladder) to a large segment of DNA. Every mutation causes a different effect on our bodies. Learn more about the role of genetics in Duchenne.

A deletion is a type of mutation where genetic material is missing. Duchenne is caused by a mutation on the dystrophin gene; the mutation may be a deletion, duplication, or other change in the gene.  Learn about genetic testing for Duchenne.

Please discuss your child's genetic test results and treatment options with your child's doctor. For AMONDYS 45 to work, exon 45 must be present in the dystrophin gene. Your child's doctor or a genetic counselor is the best person to help you understand genetic testing. Explore what genetic test results can tell you.

Because Duchenne is a progressive disease, it’s important for your child's doctor to confirm a diagnosis and identify the specific genetic mutation to guide your child's care and treatment. More about the steps to diagnosis.

Duchenne patients who receive AMONDYS 45 must have a genetic test that shows a mutation in the dystrophin gene that can be treated by skipping exon 45. Your child's doctor is best equipped to determine if your child’s mutation is amenable to treatment with AMONDYS 45. We’ve developed a Doctor Discussion Guide to help you start that important conversation.

AMONDYS 45 therapy is a weekly intravenous (IV) infusion that is always given by a healthcare provider. The medicine is usually infused over 35-60 minutes. Learn more about planning for treatment.

Infusions can be given at an infusion center, doctor's office, or your home. Discuss your options with your doctor—there are many factors to consider when deciding what’s best for your family.

Talk to your healthcare provider. If you miss a dose of AMONDYS 45, it may be administered as soon as possible after the scheduled time.

You should talk to your doctor about all the medications you are taking. Your doctor is the best person to advise you about your medicines.

The amount of AMONDYS 45 is based upon how much you weigh. The recommended dosage is 30 milligrams per kilogram of body weight, once weekly.

The instructions you get from your doctor will explain when you should contact them. Always contact your doctor if:

• You notice any redness, tenderness, bruising, swelling, warmth, or drainage at or near the infusion site
• You experience swelling, tingling, or pain at or near the port infusion site or in the arm closest to the port
• You develop a fever

*Always refer to the manufacturer’s instruction for use (IFU) guide for more information on safety and precautions and ask your healthcare provider to review the relevant instruction for use of your port with you.

When your child is prescribed AMONDYS 45, we’ll connect you with a SareptAssist dedicated Case Manager. They will provide support to get you started on treatment and throughout your journey—from helping you understand insurance benefits to providing information on treatment locations. How SareptAssist can help.

SareptAssist is our patient support program. Families are connected with dedicated Case Managers who provide information and support to help them start and stay on treatment with AMONDYS 45. How SareptAssist can help.

We developed SareptAssist, our patient support program, to help patients start and stay on therapy. You’ll have support at every step—from managing insurance approvals to coordinating drug delivery. See how to get started.

Several advocacy organizations offer Duchenne patients and families the opportunity to come together at events throughout the year. Find out more about Duchenne advocacy groups.

Once your child is prescribed AMONDYS 45, you may enroll in SareptAssist, our patient support program. Your Case Manager will start a benefits investigation on your current insurance plan and can help explain details about your coverage. How SareptAssist can help.